The roles of RNA helicases in DNA damage repair and tumorigenesis reveal precision therapeutic strategies.
The roles of RNA helicases in DNA damage repair and tumorigenesis reveal precision therapeutic strategies.
复制标题
RNA 解旋酶在 DNA 损伤修复和肿瘤发生中的作用揭示了精准治疗策略。
DOI:
10.1158/0008-5472.can-21-2187
复制
发表时间:
2022-01
期刊:
影响因子:
11.2
通讯作者:
Tan Rong
中科院分区:
文献类型:
--
作者:
Xie Jinru;Wen Ming;Zhang Jiao;Wang Zheng;Wang Meng;Qiu Yanfang;Zhao Wenchao;Zhu Fang;Yao Mianfeng;Rong Zhuoxian;Hu Wenfeng;Pei Qian;Sun Xiaoxiang;Li Jinchen;Mao Zhiyong;Sun Lun-Quan;Tan Rong
DEAD-box RNA helicases belong to a large group of RNA processing factors and play vital roles unwinding RNA helices and in ribosomal RNA biogenesis. Emerging evidence indicates that RNA helicases are associated with genome stability, yet the mechanisms behind this association remain poorly understood. In this study, we performed a comprehensive analysis of RNA helicases using multiplatform proteogenomic databases. Over 50% (28/49) of detected RNA helicases were highly expressed in multiple tumor tissues, and more than 60% (17/28) of tumor-associated members were directly involved in DNA damage repair (DDR). Analysis of repair dynamics revealed that these RNA helicases are engaged in an extensively broad range of DDR pathways. Among these factors is DDX21, which was prominently upregulated in colorectal cancer. The high expression of DDX21 gave rise to frequent chromosome exchange and increased genome fragmentation. Mechanistically, aberrantly high expression of DDX21 triggered inappropriate repair processes by delaying homologous recombination repair and increasing replication stress, leading to genome instability and tumorigenesis. Treatment with distinct chemotherapeutic drugs caused higher lethality to cancer cells with genome fragility induced by DDX21, providing a perspective for treatment of tumors with high DDX21 expression. This study revealed the role of RNA helicases in DNA damage and their associations with cancer, which could expand therapeutic strategies and improve precision treatments for cancer patients with high expression of RNA helicases.